secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK:        0000882796
Form:       8-K
Filed at:   2025-04-10T23:59:59+00:00
Accession:  0001171843-25-002147
Event type: leadership
Sentiment:  negative
Materiality: 0.65
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

BioCryst CFO Anthony Doyle resigns; CEO Stonehouse takes interim CFO role
-------------------------------------------------------------------------

- CFO Anthony Doyle resigns effective April 9, 2025; will provide transition consulting at $450/hour until May 31.
- CEO Jon P. Stonehouse appointed Interim CFO and Interim Principal Accounting Officer effective April 9.
- Company hired former public biotech CFO as financial consultant to support Stonehouse during CFO search.
- No change to Stonehouse's compensation arrangements resulting from the interim appointment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882796/000117184325002147/0001171843-25-002147-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882796/000117184325002147/f8k_040625.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-002147

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer